ReviewKidney international supplements2018
Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project.
Review in Kidney international supplements, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Challenges and strategies for managing early-to-moderate chronic kidney disease in primary care: A systematic integrative review in high-income countries.The European journal of general practice · 2026Pooled it
- Health-related quality of life in chronic kidney disease patients in low- and lower-middle income countries: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Pooled it
- Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis.BMC medicine · 2020Pooled it
- Scoping Review of Global Kidney Genetics Clinic Models and Outcomes.Kidney international reports · 2026Article
- Redox-Driven Precision Medicine for Life-Course Prevention of Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Article
- Economic vulnerability or social inequality? A global comparative analysis of their relative impact on chronic kidney disease burden.Frontiers in public health · 2026Article
- "Kidney international reports · 2025Article
- Overcoming Diagnostic Disparities in Kidney Disease: A Call to Action.Kidney international reports · 2025Article
- Pediatric Chronic Kidney Disease: Mind the Gap Between Reality and Expectations.Children (Basel, Switzerland) · 2025Review
- Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper.Global heart · 2025Review
- Preterm Birth and Kidney Health: From the Womb to the Rest of Life.Children (Basel, Switzerland) · 2024Review
- Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria.Health economics review · 2024Article
- Article
- Framework of Guidelines for Management of CKD in Asia.Kidney international reports · 2024Article
- Artificial Intelligence in Kidney Disease: A Comprehensive Study and Directions for Future Research.Diagnostics (Basel, Switzerland) · 2024Review
- Malaria guidelines fall short in diagnosing acute kidney injury.The Lancet. Global health · 2024Article
- Article
- Overview of global healthcare policies for patients with chronic kidney disease: an integrative literature review.Einstein (Sao Paulo, Brazil) · 2024Review
- Access to chronic kidney disease (CKD) care: Its barriers and facilitators in a community development block in Purba Bardhaman, West Bengal: A qualitative study.Journal of family medicine and primary care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population, providing data on this domain. Most countries were unable to access eGFR and albuminuria in their primary care settings. Only one-third of low-income countries (LICs) were able to measure serum creatinine and none were able to access eGFR or quantify proteinuria. The ability to monitor diabetes mellitus through serum glucose and glycated hemoglobin measurements was suboptimal. Pathology services were rarely available in tertiary care in LICs (12%) and lower middle-income countries (45%). While acute and chronic hemodialysis services were available in almost all countries, acute and chronic peritoneal dialysis services were rarely available in LICs (18% and 29%, respectively). Kidney transplantation was available in 79% of countries overall and in 12% of LICs. While over one-half of all countries publicly funded RRT and kidney medications with or without copayment, this was less common in LICs and lower middle-income countries. In conclusion, this study demonstrated significant gaps in services for kidney care and funding that were most apparent in LICs and lower middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.